Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (OP: SILO )

N/A UNCHANGED
Last Price Updated: 3:23 PM EDT, Sep 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1700
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
San Francisco Passes Resolution to Decriminalize Psilocybin Mushrooms
Via Investor Brand Network
This Psychedelics Company Is Undertaking A 1:50 Reverse Stock Split To Enter NASDAQ
The psychedelics landscape changes quickly. Whether large or small, every biotech company is looking for ways to further advance their research and product & services commercialization.  
Via Benzinga

Performance

More News

Read More
Study Finds Depression Symptoms in Partners Caring for Dementia Patients May Start Long Before Cognitive Decline
Via Investor Brand Network
Georgia Legislators Discuss Psychedelics for Veterans During Committee Hearing
Via Investor Brand Network
New Research Finds Link Between Psychedelic-Induced Mystical Experiences and EcoFriendly Behavior
Via Investor Brand Network
Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF
Via Investor Brand Network
Research Indicates Better Sleep Efficiency Benefits Fibromyalgia Sufferers
Via Investor Brand Network
Important Factors to Consider When Designing Psychedelic Clinical Trial Protocols
Via Investor Brand Network
Psychedelics Company Raises More than $10M in Seed Funding to Advance Ketamine Therapy
Via Investor Brand Network
Study Explains How Threatening Cues Are Refined into Fear Signals
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research
Via Investor Brand Network
Study Finds More Than 5.5 Million Adults in the US Use Hallucinogens
Via Investor Brand Network
California Senator Sees New Path to Get Psychedelics Decriminalization Bill Approved
Via Investor Brand Network
Study Finds Vitamin D May Help Alleviate Depression Symptoms
Via Investor Brand Network
Psychedelics Advocates Put DEA Under Pressure Over Right to Try Laws
Via Investor Brand Network
Second Psychedelics Initiative Fails to Qualify for Colorado Ballot
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data
Via Investor Brand Network
Study Finds Smells Experienced in Nature Boost Mental Health
Via Investor Brand Network
Leading Neuroscientist Explains How Psychedelics Alters the Brain
Via Investor Brand Network
BioMedNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes
Via Investor Brand Network
Three Clinical Trials On Psychedelic Microdosing Worth Following
Via Investor Brand Network
Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain
Via Investor Brand Network
Research Finds That Tourism, Travel May Boost Mental Health
Via Investor Brand Network
The DEA Rescinds Proposal to Ban Five Psychedelics
Via Investor Brand Network
Preclinical Ketamine Trial Shows Positive Results For Pain Conditions Like Fibromyalgia And Arthritis
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.